<DOC>
	<DOCNO>NCT00758043</DOCNO>
	<brief_summary>This study conduct learn safety effect telaprevir combination peginterferon alfa-2a ( PEG-IFN ) ribavirin ( RBV ) participant hepatitis C never treat hepatitis C virus ( HCV ) . The study design look relative benefit 24 48 week total treatment people respond quickly telaprevir-based treatment .</brief_summary>
	<brief_title>A Study Evaluating 24-Week 48-Week Telaprevir-Based Regimen Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve Extended Rapid Viral Response</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Has receive previous treatment approve investigational drug drug regimen treatment hepatitis C Male female subject , 18 70 year age , inclusive Genotype 1 , chronic hepatitis C detectable HCV RNA . Screening laboratory value , test , physical exam within acceptable range Able willing follow contraception requirement Able read understand , willing sign inform consent form abide study restriction . Subject contraindication Pegasys® Copegus® therapy Evidence hepatic decompensation cirrhotic subject History organ transplant History , current medical condition could impact safety subject participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>